Cor Vasa 2016, 58(1):e1-e3 | DOI: 10.1016/j.crvasa.2016.02.001

Dabigatran antidote idarucizumab has come to clinical practice

Jan Václavík
I. interní klinika - kardiologická, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice Olomouc, Olomouc, Česká republika

Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Václavík J. Dabigatran antidote idarucizumab has come to clinical practice. Cor Vasa. 2016;58(1):e1-3. doi: 10.1016/j.crvasa.2016.02.001.
Download citation

References

  1. Praxbind, summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003986/WC500197462.pdf, poslední přístup: 8. 2. 2016.
  2. Čihák R, Haman L, Táborský M. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Summary of the document prepared by the Czech Society of Cardiology. Cor Vasa 58 (2016) e153-e174. Go to original source...
  3. Doporučení České společnosti pro trombózu a hemostázu 2015: Postup při krvácení a perioperační management u nemocných léčených novými perorálními antikoagulancii (NOACs): dabigatran-etexilát (PRADAXA&trade), rivaroxaban (XARELTO&trade) a apixaban (ELIQUIS&trade). http://www.csth.cz/soubory/csth-postup-pri-krvaceni.pdf




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.